From Biomarkers to Novel Therapeutic Approaches in Chronic Obstructive Pulmonary Disease

Hsu-Hui Wang 1 and Shih-Lung Cheng 1,2,*

1 Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 10042, Taiwan; wangerge@gmail.com
2 Department of Chemical Engineering and Materials Science, Yuan-Ze University, Taoyuan City 320315, Taiwan
* Correspondence: shihlungcheng@gmail.com; Tel: +886-2-8966-7000 (ext. 2160); Fax: +886-2-7738-0708

Abstract: Chronic obstructive pulmonary disease (COPD) is a heterogeneous and complex disorder. In this review, we provided a comprehensive overview of biomarkers involved in COPD, and potential novel biological therapies that may provide additional therapeutic options for COPD. The complex characteristics of COPD have made the recommendation of a generalized therapy challenging, suggesting that a tailored, personalized strategy may lead to better outcomes. Existing and unmet needs for COPD treatment support the continued development of biological therapies, including additional investigations into the potential clinical applications of this approach.

Keywords: chronic obstructive pulmonary disease; biomarkers; therapeutic approaches; biologics

1. Introduction to COPD

Chronic obstructive pulmonary disease (COPD) is a primary contributor to chronic morbidity and mortality worldwide, and the population diagnosed with or dying from this disease is quite large, as COPD is the third leading cause of death and affects one-tenth of the global population [1]. The prevalence of COPD is expected to substantially increase over time, with an estimated five million annual deaths in 2006 due to COPD and its associated complications [2]. The complicated and heterogenous characteristics of COPD require the development of novel COPD therapeutic strategies that focus on lung function severity, symptoms, serum biomarkers, phenotypes, and comorbidities.

The factors that contribute to COPD development and the underlying mechanisms have been comprehensively studied. Although cigarette smoking is well recognized as a risk factor for developing COPD, no more than half of all smokers develop COPD during their lifetimes [3–5]. Early studies suggested that men were at greater risk of developing COPD than women, but recent pathological evidence suggests that women are more susceptible to COPD than men [6,7]. In addition to cigarette smoking, increased exposure to particulate matter (PM_{2.5} and PM_{10}) due to severe urban air pollution, occupational exposures, and indoor air pollution due to biomass fuel combustion can also predispose individuals to the development of COPD [8–11]. People who suffer from chronic bronchitis have also been identified as being at higher risk of COPD [12].

2. Biomarkers for the Assessment of COPD

A growing body of research has focused on the use of biomarkers in COPD. Biomarkers are considered objective indicators that can be used to differentiate between normal and pathological status or determine the response and therapeutic efficacy of pharmacological treatments. However, the reliability of biomarkers for defining the disease state has been controversial due to poor associations with various disease phenotypes and poor reproducibility across patient cohorts [13–15]. Thus far, the assessment of eosinophils appears to be the only reliable marker for determining the potential efficacy of corticosteroids [14].
Under normal conditions, eosinophils comprise 1% to 4% of total leukocytes in the peripheral blood. The differentiation of a hematopoietic stem cell into a mature eosinophil is dictated by the presence of interleukin (IL)-5 [16]. Eosinophils increase substantially in number during type 2 helper T cell (Th2)-mediated inflammation and become essential effector cells during the inflammatory response [17,18]. Eosinophils circulate in the bloodstream and transmigrate to the bronchial vascular endothelium [16]. Inflammatory signals activate or induce the expression of adhesion molecules on both the bronchial vascular endothelium and epithelium, which allow for the eosinophil infiltration of the airway [19]. Eosinophils are attracted to inflammatory tissues by chemokines, such as C-C motif chemokine ligand (CCL)5, CCL7, CCL11, CCL13, CCL15, CCL24, and CCL26, and are activated by pro-inflammatory cytokines, such as IL-3, IL-5, and granulocyte–macrophage colony-stimulating factor (GM-CSF). Activated eosinophils in the airways release pro-inflammatory cytokines to maintain an inflammatory state, causing tissue damage [20].

Although Th-2-mediated eosinophilic airway inflammation is typical, neutrophilic inflammation is more frequently observed in the context of COPD, associated with Th1-mediated inflammation driven by the response of neutrophils to bacterial colonization [21]. Approximately 10–40% of patients with COPD present a degree of eosinophil-driven inflammation under stable conditions, and an eosinophil-predominant phenotype was identified in 28% of exacerbations [22].

Recent GOLD guidelines suggest that serum eosinophil populations can be used as a marker to identify phenotypes or predict ICS responsiveness [23]. Eosinophilic inflammation in COPD is known to be treatable in COPD. Several monoclonal antibody therapies against IL-5 (mepolizumab), IL-5 receptor-alpha (benralizumab), IL-13 (tralokinumab), and IL-4 receptor-alpha (dupilumab) have been developed to target inflammatory pathways [22–25]. Patients with higher levels of serum eosinophils during stable disease display an increased tendency to suffer from frequent episodes of severe exacerbation [26]. A multicenter, randomized control study was conducted to determine the recovery rates associated with eosinophilic and non-eosinophilic exacerbations among patients with COPD [27]. Exacerbation associated with serum eosinophil counts ≥200 cells/µL or ≥2% of the total leukocyte count were defined as eosinophilic exacerbations. The length of hospital stay following corticosteroid treatments was an average of 1.5 days shorter for eosinophilic exacerbations than for non-eosinophilic exacerbations (p = 0.015) [28]. These study results indicated that acute exacerbation associated with eosinophilic inflammation might benefit from fast response to corticosteroid, leading to a shorter hospital stay. Other cohort studies demonstrated that patients with low eosinophil counts (<50 cells/µL) were strongly associated with infection, resulting in a longer average hospital stay and a lower 12-month survival rate compared with patients with high eosinophil counts (>150 cells/µL) [29]. Thus, the serum eosinophil count might serve as a practical reference for deciding whether to administer corticosteroid therapy to patients with exacerbation.

Research regarding the reliability of serum eosinophil counts for the prediction of exacerbation occurrence or ICS treatment outcomes in patients with stable COPD remains unsettled. Although many studies have provided evidence linking eosinophilia with exacerbation risk and the potential for positive therapeutic effects due to ICS, eosinophils may not be a reliable reference for COPD diagnosis [30]. A systematic review of randomized controlled trials and observational studies performed post hoc analyses to examine serum eosinophil thresholds for ICS: relative eosinophil counts ≥2%, absolute eosinophil counts ≥150 cells/µL and ≥300 cells/µL [31]. A positive association with ICS response was demonstrated for eosinophils ≥2% and ≥150 cells/µL, but not for ≥300 cells/µL. No association between ICS and the risk of moderate or severe COPD exacerbation events was identified in the observational studies [32]. Using the CHAIN and BODE cohorts, serum eosinophil levels were measured at baseline and followed for two years to investigate the prevalence and stability of high serum eosinophil levels (≥300 cells/µL) and their relationships with the risks of future exacerbations. A significant proportion of patients with COPD in the study showed fluctuations in serum eosinophil levels, with only 12–15%
of patients presenting with constantly high levels of blood eosinophils throughout the study period. No difference in the exacerbation rate was observed between patients with and without eosinophils [33].

Despite the uncertain role played by serum eosinophil levels for the prediction of COPD exacerbation events and ICS effects, a number of studies have presented evidence that blood eosinophil levels can be used to predict the ability of ICS to prevent exacerbations [34]. Patients with eosinophil counts >300 cells/µL were found to be the most likely to benefit from ICS treatment, whereas patients with eosinophil counts <100 cells/µL and >300 cells/µL were estimated to benefit from ICS treatment at various magnitudes [35]. Siddiqui et al. also demonstrated that LABA + ICS treatment achieved better therapeutic effects in patients with elevated blood eosinophil counts compared with ICS treatment alone, especially among patients with eosinophil counts ≥280 cells/µL [36]. By contrast, patients with eosinophil counts ≥2% who were treated with LABA + ICS therapy showed a significantly reduced exacerbation rate compared with placebo-treated patients, but no significant difference was observed when compared with mono-component–treated patients [37]. No significant differences in exacerbation rates were observed between the two treatment regimens for patients with relative eosinophil counts <2%. In another study, patients were grouped according to relative eosinophil counts, using a threshold of ≥2%, to evaluate the therapeutic effects of ICS (fluticasone propionate) [38]. ICS significantly reduced exacerbation rates in patients with eosinophil counts <2% compared with those treated with placebo, whereas no difference was observed for patients with eosinophil counts ≥2%. The discrepancies reported across different studies indicates that additional studies remain necessary to investigate the reliability of blood eosinophil counts as a biomarker for guiding ICS use.

Several studies have attempted to evaluate the practicality of using blood eosinophil counts to predict both treatment effects and exacerbation risks. A systematic review and meta-analysis that included five studies with a total of 124,976 patients with moderate to very severe COPD assessed the association between blood eosinophil count ≥2% and reductions in the exacerbation rate and pneumonia incidence following ICS treatment [38]. In this study, 60% of patients presented with serum eosinophil counts ≥2%. Within this patient group, patients treated with ICS showed a 17% reduction in exacerbation compared with patients without ICS treatment. However, the risk of pneumonia-related events was significantly elevated in patients with serum eosinophil counts ≥2% treated with ICS compared with those without ICS treatment. No significant difference was observed between with and without ICS treatment in patients with serum eosinophil counts <2%. Similar results were reported for a prospective observational study that aimed to evaluate the relationship between serum eosinophil counts and COPD exacerbation–related lung function loss [39]. Patients with serum eosinophil counts ≥350 cells/µL without ICS treatment experienced exacerbation events associated with a more rapid loss of lung function compared with patients who received ICS treatment. By contrast, Oshagbemi et al. reported no increase in the risk of all-cause mortality among patients who discontinued ICS treatment, regardless of the blood eosinophil counts [40].

In addition to blood eosinophil counts, other COPD biomarkers, such as serum IgE levels and fractional exhaled nitric oxide (FeNO), have been intensively investigated. Atopy refers to the hereditary tendency to generate IgE antibodies against common environmental allergens, such as proteins [41], and atopy is widely recognized to be an essential pathological factor in the development of asthma. Although the contributions of atopy to the development of COPD have not yet been fully investigated, atopy is considered a COPD risk factor [42], and the positive rate of atopy in COPD has been reported between 15% and 40% [43,44]. Bozek et al. showed that 33.3% of patients with COPD had IgE-dependent sensitization to environmental allergens compared with only 11.5% of healthy individuals [44]. In the CODE cohort, allergic sensitization in patients with COPD was associated with an increased exacerbation rate and aggravated respiratory symptoms [45].
A 3-year follow-up study demonstrated that the presence of atopy (based on the detection of a specific IgE) was positively associated with cough and chest tightness [41].

FeNO has been identified as a useful biomarker for type 2 inflammation, and the Global Initiative for Asthma recommends the use of FeNO as a reference for clinical assessment and therapeutic guidance in patients with asthma [42]. FeNO can be reproducibly measured in a non-invasive manner [46]. However, the role of FeNO in COPD remains inconclusive. A systematic review and meta-analysis including 24 studies found that FeNO levels in patients with COPD were slightly elevated compared with those in healthy individuals [47]. No association was identified between FeNO levels and COPD exacerbation. Patients with COPD who were ex-smokers showed higher FeNO levels than current smokers. A scoping review also concluded that FeNO alone could not be used in clinical settings because no FeNO cutoff value has been established for use in therapeutic guidance for COPD treatment [48]. Yamaji et al. proposed two cutoff values for FeNO for predicting ICS responsiveness: 35 ppb was able to distinguish patients with a near-certain response, whereas 20 ppb was able to exclude patients with a near-certainty of no response [49]. However, the sample size of this study was small, and the patient groups were limited to ex-smokers; therefore, future studies remain necessary to validate the applicability of these cutoff values to all patients with COPD.

3. Novel Therapeutic Approach of COPD

Current pharmacological therapies for stable COPD include bronchodilators, such as β2 agonists, and anti-inflammatories, such as corticosteroids [50]. The optimal COPD treatment strategy is determined based on symptom assessments, such as the mMRC questionnaire, the CAT, and the Clinical COPD Questionnaire (CCQ), as well as predicted future risks of disease progression and exacerbations [51], with the aim of improving symptoms and reducing future risks. Effective treatments for COPD include long-acting bronchodilators, such as LAMAs and LABAs, which reduce hyperinflation, ease COPD symptoms, and decrease exacerbations [51]. Patients with COPD commonly present with type 1 inflammation characterized by a predominant proportion of macrophages and neutrophils and increased numbers of CD8+ and CD4+ T cells [52]. Some COPD patients present with eosinophilic inflammation and the clinical features of asthma, including reversible airway obstruction, enhanced airway hyper-responsiveness, and an improved response to corticosteroid therapy [53]. Biologics targeting eosinophilic inflammation have been successful for treating severe asthma, and several cytokines, including IL-4, IL-5, and IL-13, have demonstrated promising therapeutic effects in patients with COPD. An increasing number of studies have focused on targeting neutrophilic inflammation, and an overview of current biologics that are used for COPD treatment is presented in Table 1.

| Cytokine Target | Biologics | Delivery Route | Therapeutic Effects | Reference |
|-----------------|-----------|----------------|---------------------|-----------|
| IL-5            | Mepolizumab | Subcutaneous injection every four weeks | Small reduction in exacerbations | [54] |
| IL-5Rα          | Benralizumab | Subcutaneous injection every four weeks | Minor effects on FEV₁ | [55] |
| IL-33           | Itepekimab | Two Subcutaneous injections every two weeks | Reduced exacerbation rates and improved lung function in former smokers with COPD | [56] |
| TNFα            | Infliximab | Subcutaneous injection every four weeks | No effect | [57,58] |
| IL-1β           | Canakinumab | Subcutaneous injection every eight weeks | No effect | [59] |
| CXCR2           | Navarixin (CXCR2 antagonist) | Oral administration once per day | Minor effect on FEV₁ | [60] |
3.1. Targeting Eosinophilic, Type 2 Inflammation

3.1.1. IL-5

IL-5 is among the best-studied cytokines involved in eosinophilic inflammation and is produced by CD4\(^+\) Th2 lymphocytes, innate lymphoid cells, and eosinophils. IL-5 differentiates eosinophils from precursors in the bone marrow and prolongs eosinophil survival in the airways. IL-5 and IL-5 receptors have been targeted for COPD treatment through the eosinophilic pathway [61,62]. Starting in 2000, a double-blind, randomized, placebo-controlled trial was conducted to investigate the therapeutic effects of a monoclonal antibody against IL-5 in asthma patients [63]. A single intravenous infusion of anti–IL-5 antibody resulted in a marked reduction in blood eosinophils for up to 16 weeks and a reduction in sputum eosinophils at four weeks. Anti–IL-5 (mepolizumab and reslizumab) antibodies reduce blood and sputum eosinophil counts, achieving 50% attenuation of bronchial submucosal eosinophils [64]. Additionally, a monoclonal antibody against IL-5 receptor (benralizumab) was able to induce antibody-mediated cell cytotoxicity, resulting in an even larger reduction in eosinophil populations in the bronchial submucosa [64]. A randomized, double-blind, placebo-controlled, phase 2 study was performed in multiple countries to determine whether benralizumab reduced the occurrence of acute exacerbations in patients with COPD with eosinophilia [55]. Enrolled patients were randomly assigned to receive either benralizumab or placebo for a total of 12 weeks, but no significant difference in the annual rate of acute COPD exacerbations was observed between the two groups. In a post hoc analysis, patients with blood eosinophil counts over 250 cells/µL, or sputum eosinophil counts over 2%, showed better improvements in lung function and health status, suggesting a more prominent effect of the antibody treatment for the eosinophilic group. Two phase 3, randomized, placebo-controlled, double-blind, parallel-group trials (METREX and METREO trials) were conducted to evaluate the effects of add-on subcutaneous mepolizumab treatment in frequently exacerbating patients with COPD, including the assessment of efficacy and safety [53]. The results demonstrated that mepolizumab at a dose of 100 mg was associated with a lower annual rate of moderate or severe exacerbations compared with placebo among patients with COPD with an eosinophilic phenotype, defined as a peripheral blood differential eosinophil count of 2% or more, which equates to approximately 150 to 200 eosinophils per cube millimeter. All anti–IL-5 therapies are administered once per month; mepolizumab and beralizumab can be administered by subcutaneous injection, but reslizumab is administered intravenously [65]. The side effects of anti–IL-5 therapies include headache, nasopharyngitis, and local injection reactions [66,67].

Mepolizumab is the first biologic therapy that effectively reduced the occurrence of COPD exacerbations, with studies indicating that treatment strongly reduced the severity of eosinophilic inflammation. However, additional studies are necessary to examine long-term safety and the risks of increasing exacerbations.

3.1.2. IL-4 and IL-13

IL-4 is essential for the differentiation of Th2 cells and, together with IL-13, enhances IgE secretion from B cells, increasing eosinophilic inflammation [68]. The preliminary results for IL-4 inhibitors failed to meet expectations, leading most studies to focus instead on blocking IL-13 or IL-4Ra, which can block both IL-4 and IL-13. Various approaches, including the use of decoy receptors to block IL-4Ra, have resulted in unsatisfactory outcomes due to poor target inhibition [69]. However, IL-13 increases the expression of inducible nitric oxide synthase by airway epithelial cells; therefore, FeNO has been evaluated as a biomarker for predicting the response to anti–IL-13 therapies. Treatment with lebrikizumab, an IL-13–specific blocking antibody, resulted in only slight improvements in FEV\(_1\), but no other improvements were observed for other symptoms, quality of life, or the occurrence of exacerbations [70]. The inconsistency and marginal effects of lebrikizumab were later confirmed by two phase III clinical trials, leading to the discontinuation of lebrikizumab for patients with COPD [71]. Another IL-13–blocking antibody, tralokinumab,
demonstrated neither improvements in asthma symptoms nor reductions in the occurrence of exacerbations [72]. Dupilumab, a fully human anti–IL-4α receptor monoclonal antibody, inhibits IL-4 and IL-13 and appears to be effective in patients with moderate to severe asthma, regardless of baseline serum eosinophil counts [73]. All enrolled patients with uncontrolled persistent asthma were given dupilumab as add-on therapy every two weeks over a total of 24 weeks. Reductions in annualized exacerbation rates were observed for the overall population (70–75.5%), the subgroup with >300 eosinophils per µL (71.2–80.7%), and the subgroup with <300 eosinophils per µL (59.9–67.6%). No other promising results for anti–IL-4 and anti–IL-13 therapy have been reported in COPD.

3.1.3. IL-33

IL-33 is predominately released from epithelial cells, alveolar type 2 epithelial cells, endothelial cells, mast cells, and fibroblasts [74,75]. The expression of IL-33 is stimulated by inhaled stimuli, such as allergens, infections, pollution, and cigarette smoke, leading to the activation, migration, and recruitment of innate and adaptive immune cells and the production of type 2 (Th2) cytokines, including IL-4, IL-5, and IL-13 [76,77]. In COPD, IL-33 signaling is complex. Increased IL-33 expression was found in whole lung samples obtained from patients with COPD, as well as in epithelial and endothelial cells [78,79]. IL-33 is also elevated in a caspase-4–dependent manner in peripheral blood mononuclear cells obtained from patients with COPD compared with those from healthy individuals, suggesting that IL-33 might also be an essential factor in COPD [80].

Several clinical trials have been conducted to determine the therapeutic effects of anti–IL-33 monoclonal antibodies for treating asthma and moderate to severe COPD [81]. Etokimab is an anti–IL-33 monoclonal antibody in a phase 2 proof-of-concept trial for the treatment of eosinophilic asthma. In this study, patients were given a single dose of etokimab, which resulted in improved FEV₁ and reduced blood eosinophil counts. However, etokimab had no further therapeutic effects and failed to achieve significant differences compared with placebo on the primary endpoints for the treatment of patients with chronic rhinosinusitis and nasal polyps in clinical studies; thus, etokimab has been discontinued from further development.

A recent phase 2a trial was completed for the evaluation of itepekimab, an anti–IL-33 monoclonal antibody, in patients with moderate to severe COPD on a stable regimen of triple-inhaled or double-inhaled background maintenance therapy [66]. Enrolled patients aged between 40 and 75 years who were current or former smokers diagnosed with COPD were randomly allocated to receive 300 mg itepekimab or placebo every two weeks for 24 to 52 weeks. No significant difference in the annualized rate of acute COPD exacerbations was observed between the itepekimab and placebo groups, but a minor improvement was observed in FEV₁ in the itepekimab group. When analyzing former smokers with COPD, itepekimab demonstrated a significant reduction in acute COPD exacerbations and improved FEV₁ improvement compared with placebo. However, no therapeutic benefit of itepekimab was observed in current smokers. Two phase 3 trials are ongoing to further determine the efficacy and safety of itepekimab in former smokers with COPD.

3.2. Targeting Neutrophilic, Non-Type 2 Inflammation

3.2.1. IL-17

IL-17 is produced by Th17 cells and has been described as an essential cytokine that mediates steroid-resistant neutrophilic airway diseases, such as severe asthma and COPD [82]. The rationale for evaluating IL-17 as a potential therapeutic target in COPD has been supported by in vitro data showing that IL-17 was able to induce cytokines, such as IL-6 and IL-8, for neutrophil recruitment and activation, and the inhibition of IL-17 using a monoclonal antibody resulted in a reduction in neutrophil numbers in the bronchoalveolar lavage fluid in an animal model [83]. A phase 2 clinical study was initiated to determine the efficacy and safety of the anti–IL-17 monoclonal antibody CNTO 6785 in patients with moderate to severe COPD [84]. Eligible patients were randomly assigned...
to CNTO 6785 and placebo treatment every two weeks over a total of 24 weeks. The trial did not meet any efficacy endpoints, and no significant differences in infection rates were observed between CNTO 6785 and placebo. A recent preclinical study demonstrated that the inhibition of IL-17, using either a monoclonal antibody or a small-molecule IL-17 blocker, effectively elevated glucocorticoid sensitivity in steroid-resistant neutrophilic airway inflammation [85]. This preclinical study suggested a novel mechanism for steroid resistance in type-17 neutrophilic airway inflammation, shedding light on other possible therapeutic strategies for COPD.

3.2.2. TNF

Tumor necrosis factor (TNF) appears to play a role in the pathogenesis of COPD, and several mechanisms have been described regarding the contributions of TNF to COPD pathology [86]. TNF overexpression is observed in airways, amplifying neutrophilic inflammation. TNF induces apoptosis in normal cells, and TNF might act as a major factor in the cachexia that characterizes chronic inflammation and is a known comorbidity of COPD [87]. In addition, emphysema has been associated with apoptosis in the cells of the alveolar wall, suggesting a possible mechanism through which TNF might contribute to emphysema development [88,89]. A multicenter and double-blind study was conducted to evaluate the safety and efficacy of an anti-TNF antibody (infliximab) in patients with moderate to severe COPD. Enrolled patients with severe COPD were treated with either infliximab or placebo over 24 weeks; however, the results showed no treatment benefit for improving symptoms or lung function or reducing exacerbations.

3.2.3. IL-1β

IL-1β is a primary cytokine that mediates the initiation and persistence of inflammation. A high level of IL-1 production has been reported in stable COPD, which increases during exacerbations [90]. Macrophages are the primary source of IL-1β, but other cell types can also secrete IL-1β, including neutrophils, fibroblasts, T cells, and bronchial and alveolar epithelial cells. Preclinical studies have indicated that IL-1β activity in the lung can induce phenotypes similar to those observed in COPD, including lung inflammation and emphysema [91]. Moreover, serum IL-1β levels were negatively correlated with FEV1 in patients with COPD [92]. Phase 1 and phase 2 studies have been conducted to evaluate the safety and efficacy of the anti-human IL-1β monoclonal antibody canakinumab in patients with COPD. Eligible patients with COPD were randomly assigned to receive canakinumab or placebo for a 45-week study period. The study results did not meet the primary endpoints, with no clear therapeutic effects on improvements in FEV1, FVC, SVC, or forced expiratory flow 25–75%. Whether canakinumab can serve as be an appropriate therapeutic option for COPD remains unclear.

3.2.4. CXCR2

CXC chemokine receptor 2 (CXCR2) is activated by CXC chemokines, such as CXCL1 and CXCL5, both of which are elevated in sputum from patients with COPD and increase further during exacerbations [93]. Various small-molecule CXCR2 antagonists have been studied, demonstrating the ability to inhibit the neutrophil activation and migration associated with neutrophilic airway inflammation [94]. For example, an orally administered antagonist of human CXCR2, navarixin, was evaluated in a phase 2 proof-of-concept trial to determine safety and efficacy in the treatment of COPD [60]. Patients with COPD who were either non-smokers or current smokers were randomly assigned to receive either navarixin or placebo for a 6-month period. Patients who took daily 50 mg navarixin showed a reduced sputum neutrophil count and a minor improvement in FEV1, an effect that was more prominent in current smokers than former smokers [60].

The selective CXCR2 antagonist danirixin showed potent antagonism of CXCR2 activity in preclinical studies [95]. A recent phase 2b trial was performed to evaluate the safety and therapeutic efficacy of danirixin in patients with mild to moderate COPD [96].
Enrolled patients were randomly allocated to receive danirixin or placebo for a 6-month period. Treatment with danirixin did not demonstrate any meaningful clinical benefits in improving COPD symptoms or health-related quality of life, contrasting the results of earlier studies, indicating that patients with COPD might benefit from treatment with a CXCR2 antagonist. However, the patients with COPD who were treated with danirixin experienced more exacerbations, indicating the need for further evaluations of the safety and efficacy of the CXCR2 antagonists.

4. Conclusions

In this review, we highlighted recent updates in therapeutic modalities for COPD, focused on biomarkers involved in COPD and novel therapeutic approaches using biologic therapy. We expect that this review would inspire more investigations that can facilitate further individualized therapy for COPD. Adaptations of the materials included herein for educational and training purposes are also encouraged.

Author Contributions: Conceptualization, H.-H.W. and S.-L.C.; methodology, H.-H.W.; software, H.-H.W.; validation, H.-H.W.; formal analysis, H.-H.W.; investigation, H.-H.W.; resources, H.-H.W.; data curation, H.-H.W.; writing—original draft preparation, H.-H.W.; writing—review and editing, S.-L.C.; visualization, H.-H.W.; supervision, S.-L.C.; project administration, S.-L.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: This study was supported by grants from the Far Eastern Memorial Hospital (numbers: FEMH-2021-C-042).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Halpin, D.M.G.; Criner, G.J.; Papi, A.; Singh, D.; Anzueto, A.; Martinez, F.J.; Agusti, A.A.; Vogelmeier, C.F. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 2021, 203, 24–36. [CrossRef]

2. Lopez, A.D.; Shibuya, K.; Rao, C.; Mathers, C.D.; Hansell, A.; Held, L.S.; Schmid, V.; Buist, S. Chronic obstructive pulmonary disease: Current burden and future projections. Eur. Respir. J. 2006, 27, 397–412. [CrossRef] [PubMed]

3. Lamprecht, B.; McBurnie, M.A.; Vollmer, W.M.; Gudmundsson, G.; Welte, T.; Nizankowska-Mogilnicka, E.; Studnicka, M.; Bateman, E.; Anto, J.M.; Burney, P.; et al. COPD in Never Smokers. Chest 2011, 139, 752–763. [CrossRef] [PubMed]

4. Rennard, S.I.; Vestbo, J. COPD: The dangerous underestimate of 15%. Lancet 2006, 367, 1216–1219. [CrossRef]

5. Thomsen, M.; Nordestgaard, B.G.; Vestbo, J.; Lange, P. Characteristics and outcomes of chronic obstructive pulmonary disease in never smokers in Denmark: A prospective population study. Lancet Respir. Med. 2013, 1, 543–550. [CrossRef]

6. Martinez, F.J.; Curtis, J.; Sciruba, F.; Mumford, J.; Giardino, N.D.; Weinmann, G.; Kazerooni, E.; Murray, S.; Criner, G.J.; Sin, D.D.; et al. Sex Differences in Severe Pulmonary Emphysema. Am. J. Respir. Crit. Care Med. 2007, 176, 243–252. [CrossRef]

7. Brandsma, C.; Berge, M.V.D.; Hackett, T.; Brusselle, G.; Timens, W. Recent advances in chronic obstructive pulmonary disease pathogenesis: From disease mechanisms to precision medicine. J. Pathol. 2020, 250, 624–635. [CrossRef]

8. Devries, R.; Kriebel, D.; Sama, S. Outdoor Air Pollution and COPD-Related Emergency Department Visits, Hospital Admissions, and Mortality: A Meta-Analysis. J. Chronic Obstr. Pulm. Dis. 2017, 14, 113–121. [CrossRef] [PubMed]

9. Wong, J.; Magun, B.; Wood, L. Lung inflammation caused by inhaled toxicants: A review. Int. J. Chronic Obstr. Pulm. Dis. 2016, 11, 1391–1401. [CrossRef]

10. Maas, A.; Kothe, H.; Centeno, I.P.; Leiva, M.J.G.; Dalhoff, K. Prevalence of Chronic Bronchitis and Respiratory Health Profile of a Population Exposed to Wood Smoke in Nicaragua. J. Health Pollut. 2020, 10, 200607. [CrossRef]

11. Liu, S.; Zhou, Y.; Liu, S.; Chen, X.; Zou, W.; Zhao, D.; Li, X.; Pu, J.; Huang, L.; Chen, J.; et al. Association between exposure to ambient particulate matter and chronic obstructive pulmonary disease: Results from a cross-sectional study in China. Thorax 2017, 72, 788–795. [CrossRef] [PubMed]

12. Guerra, S.; Sherrill, D.L.; Venker, C.; Ceccato, C.M.; Halonen, M.; Martinez, F.D. Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Thorax 2009, 64, 894–900. [CrossRef]
13. Vestbo, J.; Papi, A.; Corrada, M.; Blazhko, V.; Montagna, I.; Francisco, C.; Cohuet, G.; Vezzoli, S.; Scuri, M.; Singh, D. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITTY): A double-blind, parallel group, randomised controlled trial. *Lancet* 2017, 389, 1919–1929. [CrossRef]

14. Stockley, R.A.; Halpin, D.M.G.; Celli, B.R.; Singh, D. Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. *Am. J. Respir. Crit. Care Med.* 2019, 199, 1195–1204. [CrossRef]

15. Celli, B.R.; Anderson, J.A.; Brook, R.; Calverley, P.; Cowans, N.J.; Crim, C.; Dixon, I.; Kim, V.; Martinez, F.J.; Morris, A.; et al. Serum biomarkers and outcomes in patients with moderate COPD: A substudy of the randomised SUMMIT trial. *BMJ Open Respir. Res.* 2019, 6, e000431. [CrossRef] [PubMed]

16. David, B.; Bafadhel, M.; Koenderman, L.; De Soya, A. Eosinophilic inflammation in COPD: From an inflammatory marker to a treatable trait. *Thorax* 2021, 76, 188–195. [CrossRef]

17. Fulker son, P.C.; Rothenberg, M.E. Targeting eosinophils in allergy, inflammation and beyond. *Nat. Rev. Drug Discov.* 2013, 12, 117–129. [CrossRef] [PubMed]

18. George, L.; Brightling, C. Eosinophilic airway inflammation: Role in asthma and chronic obstructive pulmonary disease. *Ther. Adv. Chronic Dis.* 2016, 7, 34–51. [CrossRef]

19. Hirai, H.; Tanaka, K.; Yoshie, O.; Ogawa, K.; Kenmotsu, K.; Takamori, Y.; Ichimasa, M.; Sugamura, K.; Nakamura, M.; Takano, S.; et al. Prostaglandin D2 Selectively Induces Chemotaxis in T Helper Type 2 Cells, Eosinophils, and Basophils via Seven-Transmembrane Receptor Crth2. *J. Exp. Med.* 2001, 193, 255–262. [CrossRef]

20. Tashkin, D.P.; Wechsler, M.E. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. *Int. J. Chronic Obstr. Pulm. Dis.* 2018, 13, 335–349. [CrossRef]

21. Barnes, P.J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. *J. Allergy Clin. Immunol.* 2016, 138, 16–27. [CrossRef]

22. Bafadhel, M.; McKenna, S.; Terry, S.; Mistry, V.; Reid, C.; Haldar, P.; McCormick, M.; Haldar, K.; Kebadze, T.; Duvoix, A.; et al. Acute Exacerbations of Chronic Obstructive Pulmonary Disease. *Am. J. Respir. Crit. Care Med.* 2011, 184, 662–671. [CrossRef]

23. Bafadhel, M.; Pavord, I.D.; Russell, R. Eosinophils in COPD: Just another biomarker? *Lancet Respir. Med.* 2015, 7, 747–759. [CrossRef]

24. Bel, E.H.; Brinke, A.T. New Anti-Eosinophil Drugs for Asthma and COPD. *Drugs* 2018, 78, 505–511. [CrossRef]

25. Feng, H.-R.; Zhang, C.; Ying, S.-M. Classical and Emerging Therapies against Chronic Obstructive Pulmonary Disease. *Transmembrane Receptor Crth2. J. Exp. Med.* 2001, 193, 255–262. [CrossRef]

26. Markham, A. Benralizumab: First Global Approval. *Drugs* 2018, 78, 505–511. [CrossRef]

27. Brightling, C.; Chanez, P.; Leigh, R.; O’Byrne, P.; Korn, S.; She, D.; May, R.; Streicher, K.; Ranade, K.; Piper, E. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: A randomised, double-blind, placebo-controlled, phase 2b trial. *Lancet Respir. Med.* 2015, 3, 692–701. [CrossRef]

28. Bafadhel, M.; McKenna, S.; Terry, S.; Mistry, V.; Pancholi, M.; Venge, P.; Lomas, D.A.; Barer, M.R.; Johnston, S.L.; Pavord, I.D.; et al. Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease. *Am. J. Respir. Crit. Care Med.* 2012, 186, 48–55. [CrossRef]

29. Bafadhel, M.; Greening, N.; Harvey-Dunstan, T.C.; Williams, J.E.; Morgan, M.D.; Brightling, C.; Hussain, S.F.; Pavord, I.; Singh, S.J.; Steiner, M. Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD. *Chest* 2016, 150, 320–328. [CrossRef] [PubMed]

30. MacDonald, M.L.; Osadnik, C.R.; Bulfin, L.; Hamza, K.; Leong, P.; Wong, A.; King, P.T.; Bardin, P.G. Low and High Blood Eosinophil Counts as Biomarkers in Hospitalized Acute Exacerbations of COPD. *Chest* 2019, 156, 92–100. [CrossRef]

31. Zysman, M.; Deslee, G.; Cairaud, D.; Chanez, P.; Escamilla, R.; Court-Fortune, I.; Nesme-Meyer, P.; Perez, T.; Paillas, J.L.; Pinet, C.; et al. Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. *Int. J. Chronic Obstr. Pulm. Dis.* 2017, 12, 1819–1824. [CrossRef]

32. Harries, T.H.; Rowland, V.; Corrigan, C.J.; Marshall, I.J.; McDonnell, L.; Prasad, V.; Schofield, P.; Armstrong, D.; White, P. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: Systematic review and meta-analysis. *Respir. Res.* 2020, 21, 1–15. [CrossRef]

33. Casanova, C.; Celli, B.R.; de Torres, J.P.; Martinez, C.; Consolo, B.G.; Pinto-Plata, V.; De Lucas-Ramos, P.; Divo, M.; Fuster, A.; Peces-Barba, G.; et al. Prevalence of persistent blood eosinophilia: Relation to outcomes in patients with COPD. *Eur. Respir. J.* 2017, 50, 1701162. [CrossRef] [PubMed]

34. Lipson, D.; Barnhart, F.; Brealey, N.; Brooks, J.; Criner, G.J.; Day, N.C.; Dransfield, M.T.; Halpin, D.M.; Han, M.K.; Jones, C.E.; et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. *N. Engl. J. Med.* 2018, 378, 1671–1680. [CrossRef] [PubMed]

35. Bafadhel, M.; Peterson, S.; De Blas, M.A.; Calverley, P.M.; Rennard, S.I.; Richter, K.; Fagerás, M. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: A post-hoc analysis of three randomised trials. *Lancet Respir. Med.* 2018, 6, 117–126. [CrossRef]

36. Siddiqui, S.; Guasconi, A.; Vestbo, J.; Jones, P.; Agusti, A.; Paggiaro, P.; Wedzicha, J.A.; Singh, D. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. *Am. J. Respir. Crit. Care Med.* 2015, 192, 523–525. [CrossRef]
37. Pauw, I.; Lettis, S.; Locantore, N.; Pascoe, S.; Jones, P.W.; Wedzicha, J.A.; Barnes, N.C. Blood eosinophils and inhaled corticosteroid/long-acting β2 agonist efficacy in COPD. Thorax 2016, 71, 118–125. [CrossRef] [PubMed]

38. Cheng, S.-L.; Blood eosinophils and inhaled corticosteroids in patients with COPD: Systematic review and meta-analysis. Int. J. Chronic Obstr. Pulm. Dis. 2018, 13, 2775–2784. [CrossRef]

39. Kerkhoff, M.; Voonham, J.; Forinsky, P.; Cabrera, C.; Darken, P.; Kocks, J.W.; Sadatsafavi, M.; Sin, D.D.; Carter, V.; Price, D.B. Association between COPD exacerbations and lung function decline during maintenance therapy. Thorax 2020, 75, 744–753. [CrossRef]

40. Oshagbemi, O.A.; Franssen, F.M.; van Kraaitj, S.; Braeken, D.C.; Wouters, E.F.; der Zee, A.H.M.-V.; Driessen, J.H.; de Vries, F. Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD). J. Chronic Obstr. Pulm. Dis. 2019, 16, 152–159. [CrossRef]

41. Faffah, F.; Hacken, N.H.T.T.; Löfdahl, C.-G.; Hylkema, M.N.; Timens, W.; Postma, D.S.; Vonk, J.M. Atopy is a risk factor for respiratory symptoms in COPD patients: Results from the EUROSCOP study. Respir. Res. 2013, 14, 10. [CrossRef]

42. Oishi, K.; Matsunaga, K.; Shirai, T.; Hirai, K.; Kon, Y. Role of Type2 Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease. J. Clin. Med. 2020, 9, 2670. [CrossRef]

43. Neves, M.C.L.C.; Neves, Y.C.S.; Mendes, C.M.C.; Bastos, M.N.; Camelier, A.; Queiroz, C.F.; Mendoza, B.F.; Lemos, A.C.M.; Junior, A.D. Evaluation of atopy in patients with COPD. J. Bras. Pneumol. 2013, 39, 296–305. [CrossRef]

44. Bozek, A.; Rogala, B. IgE-dependent sensitization in patients with COPD. Ann. Agric. Environ. Med. 2018, 25, 417–420. [CrossRef]

45. Jamieson, D.B.; Matsui, E.C.; Belli, A.; McCormack, M.C.; Peng, E.; Pierre-Louis, S.; Curtin-Brosnan, J.; Breyssse, P.N.; Diette, G.B.; Hansel, N.N. Effects of Allergic Phenotype on Respiratory Symptoms and Exacerbations in Patients with Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 2013, 188, 187–192. [CrossRef]

46. Bjermer, L.; Alving, K.; Diamant, Z.; Magnussen, H.; Pavord, I.; Piacentini, G.; Price, D.; Roche, N.; Sastre, J.; Thomas, M.; et al. Current evidence and future research needs for FeNO measurement in respiratory diseases. Respir. Med. 2014, 108, 830–841. [CrossRef] [PubMed]

47. Lu, Z.; Huang, W.; Wang, L.; Xu, N.; Ding, Q.; Cao, C. Exhaled nitric oxide in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. Int. J. Chronic Obstr. Pulm. Dis. 2018, 13, 2695–2705. [CrossRef]

48. Mostafavi-Pour-Manshadi, S.-M.-Y.; Naderi, N.; Barrecheguren, M.; Dehghan, A.; Bourbeau, J. Investigating Fractional Exhaled Nitric Oxide in Chronic Obstructive Pulmonary Disease (COPD) and Asthma-COPD Overlap (ACO): A Scoping Review. COPD J. Chronic Obstr. Pulm. Dis. 2018, 15, 377–391. [CrossRef] [PubMed]

49. Yamaji, Y.; Oishi, K.; Kamada, K.; Ohteru, Y.; Chikumoto, A.; Murakawa, K.; Matsuoka, K.; Suetake, R.; Murata, Y.; Ito, K.; et al. Detection of type2 biomarkers for response in COPD. J. Breath Res. 2014, 18, 026007. [CrossRef] [PubMed]

50. Yousuf, A.; Ibrahim, W.; Greening, N.J.; Brightling, C.E. T2 Biologics for Chronic Obstructive Pulmonary Disease. J. Allergy Clin. Immunol. Pract. 2019, 7, 1405–1416. [CrossRef] [PubMed]

51. Postma, D.S.; Rabe, K.F. The Asthma−COPD Overlap Syndrome. N. Engl. J. Med. 2015, 373, 1241–1249. [CrossRef]

52. Barnes, P.J. Asthma-COPD Overlap. Chest 2016, 149, 7–8. [CrossRef]

53. Pavord, I.D.; Chaney, P.; Criner, G.J.; Kerstjens, H.; Korn, S.; Lugogo, N.; Martinot, J.-B.; Sagara, H.; Albers, F.C.; Bradford, E.S.; et al. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 2017, 377, 1613–1629. [CrossRef]

54. Dargupta, A.; Kjarsgaard, M.; Capaldi, D.; Radford, K.; Alaman, I.; Altman, L.C.; Wright, T.N.; Parraga, G.; O’Byrne, P.; et al. A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis. Eur. Respir. J. 2017, 49, 1602486. [CrossRef]

55. Brightling, C.E.; Bleecker, E.R.; Panettieri, R.A.; Bafadhel, M.; She, D.; Ward, C.K.; Xu, X.; Birrell, C.; van der Merwe, R. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: A randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir. Med. 2014, 2, 891–901. [CrossRef]

56. Rabe, K.F.; Celli, B.R.; Wechsler, M.E.; Abdullai, R.M.; Luo, X.; Boomsma, M.M.; Staudinger, H.; Horowitz, J.E.; Baras, A.; Ferreira, M.A.; et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: A genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir. Med. 2021. [CrossRef]

57. Sissa, S.; Ernst, P.; Hudson, M. TNF-α antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2008, 21, 234–238. [CrossRef] [PubMed]

58. Wenzel, S.E.; Barnes, P.J.; Bleecker, E.R.; Bousquet, J.; Busse, W.; Dahlén, S.-E.; Holgate, S.T.; Meyers, D.A.; Rabe, K.F.; Antczak, A.; et al. A Randomized, Double-blind, Placebo-controlled Study of Tumor Necrosis Factor-α Blockade in Severe Persistent Asthma. Am. J. Respir. Crit. Care Med. 2009, 179, 549–558. [CrossRef] [PubMed]

59. Rogliani, P.; Calzetta, L.; Ora, J.; Mares, M.G. Canakinumab for the treatment of chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2015, 31, 15–27. [CrossRef] [PubMed]

60. Rennard, S.I.; Dale, D.C.; Donohue, J.F.; Kannies, F.; Magnussen, H.; Sutherland, E.R.; Watz, H.; Su, S.; Stryszak, P.; Rosenberg, E.; et al. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 2015, 191, 1001–1011. [CrossRef] [PubMed]

61. Molin, N.A.; Gossage, D.; Kolbeck, R.; Parker, J.M.; Geba, G.P. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin. Exp. Allergy 2012, 42, 712–737. [CrossRef]
62. Leckie, M.J.; Brinke, A.T.; Khan, J.; Diamant, Z.; O’Connor, B.J.; Walls, C.M.; Mathur, A.; Cowley, H.C.; Chung, K.F.; Djukanovic, R.; et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. *Lancet* 2000, 356, 2144–2148. [CrossRef]

63. Cabon, Y.; Molinari, N.; Marin, G.; Vachier, J.; Gamez, A.S.; Chanez, P.; Bourdin, A. Comparison of anti-interleukin-5 therapies in patients with severe asthma: Global and indirect meta-analyses of randomized placebo-controlled trials. *Clin. Exp. Allergy* 2017, 47, 129–138. [CrossRef]

64. Saco, T.V.; Pepper, A.N.; Lockey, R.F. Benralizumab for the treatment of asthma. *Expert Rev. Clin. Immunol.* 2017, 13, 405–413. [CrossRef] [PubMed]

65. Barnes, P.J. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. *Nat. Rev. Immunol.* 2018, 18, 454–466. [CrossRef]

66. Leung, E.; Al Efraij, K.; Fitzgerald, J. The safety of mepolizumab for the treatment of asthma. *Expert Opin. Drug Saf.* 2017, 16, 397–404. [CrossRef] [PubMed]

67. Lugogo, N.; Domingo, C.; Chanez, P.; Leigh, R.; Gilson, M.J.; Price, R.; Yancey, S.W.; Ortega, H.G. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase Illb Study. *Clin. Ther.* 2016, 38, 2058–2070.e2051. [CrossRef] [PubMed]

68. Kasaian, M.T.; Miller, D.K. IL-13 as a therapeutic target for respiratory disease. *Biochem. Pharmacol.* 2008, 76, 147–155. [CrossRef] [PubMed]

69. Antoniu, S. Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema. *Curr. Opin. Investig. Drugs* 2010, 11, 1286–1294. [PubMed]

70. Corren, J.; Lemanske, R.F.; Hanania, N.A.; Korenblat, P.E.; Parsey, M.V.; Arron, J.; Harris, J.M.; Scheeren, H.; Wu, L.C.; Su, Z.; et al. Lebrikizumab Treatment in Adults with Asthma. *N. Engl. J. Med.* 2011, 365, 1088–1098. [CrossRef] [PubMed]

71. Hanania, N.A.; Noonan, M.; Corren, J.; Korenblat, P.; Zheng, Y.; Fischer, S.K.; Cheu, M.; Putnam, W.S.; Murray, E.; Scheeren, H.; et al. Lebrikizumab in moderate-to-severe asthma: Pooled data from two randomised placebo-controlled studies. *Thorax* 2015, 70, 748–756. [CrossRef] [PubMed]

72. Piper, E.; Brightling, C.; Niven, R.; Oh, C.; Faggioni, R.; Poon, K.; She, D.; May, R.; Geba, G.P.; et al. A Phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. *Eur. Respir. J.* 2012, 41, 330–338. [CrossRef] [PubMed]

73. Wenzel, S.; Castro, M.; Corren, J.; Maspero, J.; Wang, L.; Zhang, B.; Pirozzi, G.; Sutherland, E.R.; Evans, R.R.; Joish, V.N.; et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: A randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. *Lancet* 2016, 388, 31–44. [CrossRef] [PubMed]

74. Donovan, C.; Bourke, J.E.; Vlahos, R. Targeting the IL-33/IL-13 Axis for Respiratory Viral Infections. *Trends Pharmacol. Sci.* 2016, 37, 252–261. [CrossRef]

75. Li, Q.; Hu, Y.; Chen, Y.; Lv, Z.; Wang, J.; An, G.; Du, X.; Wang, H.; Corrigan, C.J.; Wang, W.; et al. IL-33 induces production of autoantibody against autologous respiratory epithelial cells: A potential mechanism for the pathogenesis of COPD. *Immunology* 2019, 157, 137–150. [CrossRef] [PubMed]

76. Hansbro, P.M.; Kaiko, G.E.; Foster, P.S. Cytokine/anti-cytokine therapy—Novel treatments for asthma? *Br. J. Pharmacol.* 2011, 163, 81–95. [CrossRef] [PubMed]

77. Hansbro, P.M.; Scott, G.V.; Essilfie, A.-T.; Kim, R.Y.; Starkey, M.R.; Nguyen, D.H.; Allen, P.D.; Kaiko, G.E.; Yang, M.; Horvat, J.C.; et al. Th2 cytokine antagonists: Potential treatments for severe asthma. *Expert Opin. Investig. Drugs* 2012, 22, 49–69. [CrossRef] [PubMed]

78. Byers, D.; Alexander-Brett, J.; Patel, A.; Agapov, E.; Dang-Vu, G.; Jin, X.; Wu, K.; You, Y.; Alevy, Y.; Girard, J.-P.; et al. Long-term IL-33–producing epithelial progenitor cells in chronic obstructive lung disease. *J. Clin. Investig.* 2013, 123, 3967–3982. [CrossRef]

79. Xia, J.; Zhao, J.; Shang, J.; Li, M.; Zeng, Z.; Zhao, J.; Wang, J.; Xu, Y.; Xie, J. Increased IL-33 expression in chronic obstructive pulmonary disease. *Am. J. Physiol. Cell. Mol. Physiol.* 2015, 308, L619–L627. [CrossRef]

80. De Falco, G.; Colarusso, C.; Terlizzi, M.; Popolo, A.; Pecoraro, M.; Commodo, M.; Minutolo, P.; Sirignano, M.; D’Anna, A.; Aquino, R.P.; et al. Chronic Obstructive Pulmonary Disease-Derived Culturing Cells Release IL-18 and IL-33 under Ultrafine Particulate Matter Exposure in a Caspase-1/8-Independent Manner. *Front. Immunol.* 2017, 8, 1415. [CrossRef]

81. Donovan, C.; Hansbro, P. IL-33 in Chronic Respiratory Disease: From Preclinical to Clinical Studies. *ACS Pharmacol. Transl. Sci.* 2020, 3, 56–62. [CrossRef]

82. Le Rouzic, O.; Pichavant, M.; Frealle, E.; Guillou, A.; Si-Tahar, M.; Gosset, P. Th17 cytokines: Novel potential therapeutic targets for COPD pathogenesis and exacerbations. *Eur. Respir. J.* 2017, 50, 1602434. [CrossRef] [PubMed]

83. Shen, N.; Wang, J.; Zhao, M.; Pei, F.; He, B. Anti-interleukin-17 antibodies attenuate airway inflammation in tobacco-smoke-exposed mice. *Inhal. Toxicol.* 2011, 23, 212–218. [CrossRef]

84. Eich, A.; Urban, V.; Jutel, M.; Vlcek, J.; Shim, J.J.; Trofimov, V.I.; Lian, C.-K.; Kuo, P.-H.; Hou, Y.; Xiao, J.; et al. A Randomized, Placebo-Controlled Phase 2 Trial of CTN06785 in Chronic Obstructive Pulmonary Disease. *J. Chronic Obstr. Pulm. Dis.* 2017, 14, 476–483. [CrossRef] [PubMed]

85. Ouyang, S.; Liu, C.; Xiao, J.; Chen, X.; Lui, A.C.; Li, X. Targeting IL-17A/glucocorticoid synergy to CSF3 expression in neutrophilic airway diseases. *JCI Insight* 2020, 5, 5. [CrossRef] [PubMed]
86. Sakao, S.; Tatsumi, K.; Igari, H.; Shino, Y.; Shirasawa, H.; Kuriyama, T. Association of tumor necrosis factor alpha gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* 2001, 163, 420–422. [CrossRef]

87. Sharma, R.; Anker, S.D. Cytokines, apoptosis and cachexia: The potential for TNF antagonism. *Int. J. Cardiol.* 2002, 85, 161–171. [CrossRef]

88. Zheng, T.; Kang, M.J.; Crothers, K.; Zhu, Z.; Liu, W.; Lee, C.G.; Rabach, L.A.; Chapman, H.A.; Homer, R.; Aldous, D.; et al. Role of Cathepsin S-Dependent Epithelial Cell Apoptosis in IFN-γ-Induced Alveolar Remodeling and Pulmonary Emphysema. *J. Immunol.* 2005, 174, 8106–8115. [CrossRef]

89. Saetta, M.; Turato, G.; Maestrelli, P.; Mapp, C.E.; Fabbri, L.M. Cellular and Structural Bases of Chronic Obstructive Pulmonary Disease. *Am. J. Respir. Crit. Care Med.* 2001, 163, 1304–1309. [CrossRef]

90. Chung, K.F. Cytokines in chronic obstructive pulmonary disease. *Eur. Respir. J. Suppl.* 2001, 34, 50–59. [CrossRef]

91. Lappalainen, U.; Whitsett, J.A.; Wert, S.E.; Tichelaar, J.W.; Bry, K. Interleukin-1β Causes Pulmonary Inflammation, Emphysema, and Airway Remodeling in the Adult Murine Lung. *Am. J. Respir. Cell Mol. Biol.* 2005, 32, 311–318. [CrossRef] [PubMed]

92. Singh, M.; Lee, S.-H.; Porter, P.; Xu, C.; Ohno, A.; Atmar, R.L.; Greenberg, S.B.; Bandi, V.; Germ, J.; Amineva, S.; et al. Human rhinovirus proteinase 2A induces TH1 and TH2 immunity in patients with chronic obstructive pulmonary disease. *J. Allergy Clin. Immunol.* 2010, 125, 1369–1378.e1362. [CrossRef] [PubMed]

93. Ha, H.; Debnath, B.; Neamati, N. Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases. *Theranostics* 2017, 7, 1543–1588. [CrossRef] [PubMed]

94. Dwyer, M.P.; Yu, Y. CXCR2 receptor antagonists: A medicinal chemistry perspective. *Curr. Top. Med. Chem.* 2014, 14, 1590–1605. [CrossRef]

95. Busch-Petersen, J.; Carpenter, D.C.; Burman, M.; Foley, J.; Hunsberger, G.E.; Kilian, D.J.; Salmon, M.; Mayer, R.J.; Yonchuk, J.; Tal-Singer, R. Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2. *J. Pharmacol. Exp. Ther.* 2017, 362, 338–346. [CrossRef]

96. Lazaar, A.L.; Miller, B.E.; Donald, A.C.; Keeley, T.; Ambery, C.; Russell, J.; Watz, H.; Tal-Singer, R.; Bardin, P.; Bremner, P.; et al. CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: A phase 2b trial. *Respir. Res.* 2020, 21, 149. [CrossRef]